Challenges in the Secondary Manufacture of Encapsulated High-Potency Drugs - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Challenges in the Secondary Manufacture of Encapsulated High-Potency Drugs
Liquid and semisolid encapsulation using two-piece hard capsules is an ideal drug delivery approach for highly potent compounds and poorly water-soluble drugs. The authors detail the factors to reduce risk when designing and operating a facility for secondary manufacturing of highly potent drugs.

Pharmaceutical Technology

Figure 3
Griffiths has produced a comprehensive review of safety as a design feature in secondary manufacturing that includes a "protection-cascade" approach (7). This approach involves multilevel containment by which the primary concern is the facility's ability to ensure product quality, worker safety, and protection of the external environment. It supports the concept that the project and operations teams must provide a clearly defined system of overlapping layers of protection and control throughout a facility and its operations (see Figure 3).

Example of the manufacture of two-piece, hard-shell, liquid-fill capsules.
The ability to efficiently clean through effective validation procedures is a critical design aspect in the construction of a general-purpose high-potency facility. The overall elements as part of the people, process, prefacility construction, and equipment planning process are as follows:
  • Training programs
  • Ensure that internal trainers are appropriately trained, and that training is maintained by using external expertise
  • Undertake regular training and maintain appropriate records for supervisory and operational staff
  • Increase the profile and importance of safety from the board down to operators
  • Safety evaluation
  • Review all and any relevant safety data and request toxicological and clinical data from the originator and evaluate the data against occupational health categories
  • Undertake an evaluation of the physical and chemical properties, particularly particle size, explosive or static- electricity potential
  • Undertake a thorough evaluation of the containment that will be required to carry out the specified processing and ensure that the processes are in place for further checking and validation
  • OEL definition
  • Using available data (or analogy to similar compounds), define the safe OEL limit
  • Implement industrial-hygiene sampling and develop analytical methods for monitoring exposure
  • Design-containment strategy
  • Design and communicate the containment approach for actual and perceived potential hazards
  • Define the isolation technology to be used, ventilation, and other processing equipment that will be required
  • Standard operating procedures
  • Develop appropriate procedures for handling and disposal of high-potency compounds, including cleaning and validation of all equipment
  • Ensure that written procedures for all aspects of the process are fit for purpose and relate to the level of OEL for that compound
  • Verification
  • Validate performance of engineering controls by monitoring each step of the process being undertaken
  • Undertake continuous health surveillance during the operation
  • Environmental
  • Assess the environmental impact, particularly in terms of waste disposal
  • Undertake an environmental assessment.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: Pharmaceutical Technology,
Click here